Oxford/AZ Vaccine Hits 70% Efficacy In Phase III Trials
90% Response Seen In Half Dose Trial
Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
